PL3197442T3 - Leczenie i zapobieganie chorobie czynnikami obniżającymi TMA i TMAO - Google Patents

Leczenie i zapobieganie chorobie czynnikami obniżającymi TMA i TMAO

Info

Publication number
PL3197442T3
PL3197442T3 PL15843415T PL15843415T PL3197442T3 PL 3197442 T3 PL3197442 T3 PL 3197442T3 PL 15843415 T PL15843415 T PL 15843415T PL 15843415 T PL15843415 T PL 15843415T PL 3197442 T3 PL3197442 T3 PL 3197442T3
Authority
PL
Poland
Prior art keywords
tmao
tma
treating
lowering agents
preventing disease
Prior art date
Application number
PL15843415T
Other languages
English (en)
Inventor
Stanley L. Hazen
Original Assignee
The Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Cleveland Clinic Foundation filed Critical The Cleveland Clinic Foundation
Publication of PL3197442T3 publication Critical patent/PL3197442T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15843415T 2014-09-26 2015-09-25 Leczenie i zapobieganie chorobie czynnikami obniżającymi TMA i TMAO PL3197442T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462056168P 2014-09-26 2014-09-26
PCT/US2015/052380 WO2016049541A2 (en) 2014-09-26 2015-09-25 Treating and preventing disease with tma and tmao lowering agents
EP15843415.9A EP3197442B1 (en) 2014-09-26 2015-09-25 Treating and preventing disease with tma and tmao lowering agents

Publications (1)

Publication Number Publication Date
PL3197442T3 true PL3197442T3 (pl) 2020-02-28

Family

ID=55582099

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15843415T PL3197442T3 (pl) 2014-09-26 2015-09-25 Leczenie i zapobieganie chorobie czynnikami obniżającymi TMA i TMAO

Country Status (6)

Country Link
US (7) US20160089386A1 (pl)
EP (2) EP3197442B1 (pl)
CA (1) CA2962424C (pl)
ES (1) ES2747234T3 (pl)
PL (1) PL3197442T3 (pl)
WO (2) WO2016049541A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2925346A1 (fr) 2012-11-30 2015-10-07 Universite d'Auvergne Clermont I Utilisation de microorganismes pour diminuer le taux de triméthylamine dans une cavité du corps humain, notamment pour le traitement de la triméthylaminurie ou d'une vaginose bactérienne et la prévention des maladies cardiovasculaires
WO2016049541A2 (en) 2014-09-26 2016-03-31 The Cleveland Clinic Foundation Treating and preventing disease with tma and tmao lowering agents
WO2018236899A1 (en) 2017-06-19 2018-12-27 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the tma/fmo3/tmao pathway
KR20200052298A (ko) * 2017-08-14 2020-05-14 소마젠 인크 트리메틸아민 및/또는 트리메틸아민 n-옥사이드 관련 표적화된 약물
US12576055B2 (en) 2018-02-01 2026-03-17 The Cleveland Clinic Foundation Disease detection and treatment based on trimethyl-lysine levels
CN108179128A (zh) * 2018-03-12 2018-06-19 新疆农业大学 一种羔羊粪菌液的制备方法
US12162902B2 (en) * 2018-12-06 2024-12-10 Sail Biomedicines Decarboxylase inhibitors for treating Parkinson's disease
CN110279863B (zh) * 2019-07-29 2022-02-22 牡丹江医学院 用于治疗泌尿疾病的药物组合物及其制剂
CN111983112A (zh) * 2020-09-09 2020-11-24 南京诺禾致源生物科技有限公司 血清中tmao及其相关代谢物的检测方法
CN112029818A (zh) * 2020-09-18 2020-12-04 中国药科大学 一种利用微生物筛选三甲胺裂解酶抑制剂的方法
CN114763519B (zh) * 2021-01-12 2025-07-22 生合生物科技股份有限公司 食淀粉乳杆菌lam1345分离株及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2676224B1 (fr) * 1991-05-10 1996-08-02 Jean Marie Gastaud Nouveaux sels d'ammonium quaternaire, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant.
WO2001082864A2 (en) * 2000-04-28 2001-11-08 Duke University 18f-labeled choline analogs
EP1392870B1 (en) 2001-05-09 2008-02-27 Discoverx, Inc. Screening for enzyme inhibitors
DE10248619A1 (de) * 2002-10-18 2004-04-29 Bayer Ag Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden
KR101135260B1 (ko) 2003-10-22 2012-04-12 가부시키가이샤 쿠레하 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제
EP1765433B1 (en) 2004-06-21 2016-05-18 Hemolife Medical, Inc. Plasma detoxification and volume control system
WO2007035596A2 (en) 2005-09-19 2007-03-29 Mastertaste Inc. Metal organic framework odor sequestration and fragrance delivery
CN101157667A (zh) * 2007-11-12 2008-04-09 天津工业大学 一种吗啉季铵盐型离子液体及其制备方法
CA2790371C (en) * 2009-05-28 2020-09-01 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
US9265736B2 (en) * 2011-02-10 2016-02-23 The Cleveland Clinic Foundation Treatment of cardiovascular disease and thrombosis
AU2013274406B2 (en) * 2012-06-11 2017-02-02 The Cleveland Clinic Foundation Treatment and prevention of cardiovascular disease and thrombosis
LV14848B (lv) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija trimetilamīna-N-oksīda līmeņa pazemināšanai
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
WO2016049541A2 (en) 2014-09-26 2016-03-31 The Cleveland Clinic Foundation Treating and preventing disease with tma and tmao lowering agents
WO2018236899A1 (en) * 2017-06-19 2018-12-27 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the tma/fmo3/tmao pathway

Also Published As

Publication number Publication date
WO2016049541A3 (en) 2016-06-16
CA2962424A1 (en) 2016-03-31
US9694020B2 (en) 2017-07-04
US20190038642A1 (en) 2019-02-07
US20160089386A1 (en) 2016-03-31
US10933072B2 (en) 2021-03-02
ES2747234T3 (es) 2020-03-10
WO2016049541A2 (en) 2016-03-31
US20240165131A1 (en) 2024-05-23
EP3569232A1 (en) 2019-11-20
US20170266208A1 (en) 2017-09-21
US20160089387A1 (en) 2016-03-31
CA2962424C (en) 2024-04-30
US10117879B2 (en) 2018-11-06
WO2016049537A1 (en) 2016-03-31
US20200197417A1 (en) 2020-06-25
EP3197442B1 (en) 2019-07-03
EP3197442A2 (en) 2017-08-02
US11911399B2 (en) 2024-02-27
EP3197442A4 (en) 2018-04-04
US20210186991A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
IL325256A (en) FAP-activated medical materials and related uses
PL3197442T3 (pl) Leczenie i zapobieganie chorobie czynnikami obniżającymi TMA i TMAO
IL255577B (en) Binding materials - tigit and their uses
IL253433A0 (en) Binders - tnfrsf and their uses
IL259570A (en) Combined therapy and their uses and methods
IL250331A0 (en) Flagellin-based agents and uses including effective vaccination
GB201506913D0 (en) Inductor structure and application thereof
GB201403093D0 (en) Therapeutic compounds and their use
PL3362449T3 (pl) Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową
GB201616439D0 (en) Compounds and uses
GB201608779D0 (en) Methods and compounds
IL255092A0 (en) Combined treatments with srivantumab
IL248424A0 (en) Neuroprotective substances and their uses
GB201608776D0 (en) Methods and compounds
IL252904A0 (en) Methods and factors for treating diseases
GB201404372D0 (en) Assay and treatment
PL3129398T3 (pl) Nowe środki medyczne i ich zastosowanie
GB201418809D0 (en) Therapeutic agents and uses thereof
SG10201912843YA (en) Sleep improving agent
SG11201610349SA (en) Dosing regimens for treating and/or preventing cerebral amyloidoses
PT3150778T (pt) Cadeira de suspensão em altura
IL253435A0 (en) Structures and methods for placement
GB2530711B (en) Security composition and use thereof
GB201403262D0 (en) Dog safety latch
GB201609178D0 (en) With my permission